ORXOF Stock Chart & Stats
$1.77
-$0.33(-15.71%)
At close: 4:00 PM EDT
$1.77
-$0.33(-15.71%)
Day’s Range― - ―
52-Week Range$1.41 - $4.09
Previous CloseN/A
Volume5.88K
Average Volume (3M)66.00
Market Cap
$53.99M
Enterprise Value$576.03
Total Cash (Recent Filing)$276.90M
Total Debt (Recent Filing)$9.90M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Oct 22, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.81
Shares Outstanding35,127,056
10 Day Avg. Volume0
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.12
Price to Sales (P/S)40.09
P/FCF Ratio6.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.94
Revenue Forecast (FY)$2.70M
Bulls Say, Bears Say
Bulls Say
Improved SolvencyTrailing-twelve-month leverage has materially improved, leaving Orexo with very low reported debt versus equity. Lower structural leverage reduces refinancing and interest risks, giving management more optionality to fund development, negotiate partnerships, and withstand regulatory or commercial delays over the next 2–6 months.
Positive Operating/free Cash FlowA shift to positive operating and free cash flow on a TTM basis is a durable improvement in cash generation versus prior multi-year burn. This reduces immediate financing pressure, helps preserve runway for clinical programs, and supports business development or milestone-driven funding over the medium term if cash conversion remains stable.
Strong IP And Platform ValueLong-dated exclusivity for OX640 (to 2044) and potential GLP-1 extensions (to 2047), plus the AmorphOX thermostability platform, create durable competitive assets. These structural IP advantages support long-term licensing, premium pricing potential, and partner interest for biologics/vaccine programs, underpinning multi-year commercial optionality.
Bears Say
Persistent UnprofitabilityThe core business remains structurally loss-making with negative gross profit and steep operating and net margins. Sustained losses erode shareholder equity generation, limit reinvestment capacity, and make the company reliant on external financing or partnerships to fund growth, representing a multi-month durability risk until commercial margins recover.
Ongoing DOJ Legal UncertaintyAn unresolved DOJ investigation is a structural overhang that can drive litigation costs, potential settlement payments, and insurance reliance. This uncertainty impairs financing flexibility, complicates partner negotiations and long-term planning, and may require multi-quarter legal spend and contingency planning until a definitive resolution is reached.
High Near-term Development Spend And Cash BurnMaterial quarter-on-quarter cash burn combined with a flagged SEK ~200m external cost envelope for OX640 concentrates funding needs in H2 2027–H1 2028. Unless partners assume costs or additional financing is secured, this structural spending profile risks shortening runway, increasing dilution risk, or forcing program timing changes over the coming 2–6 months.
Orexo AB News
ORXOF FAQ
What was Orexo AB’s price range in the past 12 months?
Orexo AB lowest stock price was $1.41 and its highest was $4.09 in the past 12 months.
What is Orexo AB’s market cap?
Orexo AB’s market cap is $53.99M.
When is Orexo AB’s upcoming earnings report date?
Orexo AB’s upcoming earnings report date is Oct 22, 2026 which is in 78 days.
How were Orexo AB’s earnings last quarter?
Orexo AB released its earnings results on Jul 16, 2026. The company reported -$0.228 earnings per share for the quarter, missing the consensus estimate of -$0.166 by -$0.062.
Is Orexo AB overvalued?
According to Wall Street analysts Orexo AB’s price is currently Overvalued.
Does Orexo AB pay dividends?
Orexo AB does not currently pay dividends.
What is Orexo AB’s EPS estimate?
Orexo AB’s EPS estimate is -0.22.
How many shares outstanding does Orexo AB have?
Orexo AB has 35,127,056 shares outstanding.
What happened to Orexo AB’s price movement after its last earnings report?
Orexo AB reported an EPS of -$0.228 in its last earnings report, missing expectations of -$0.166. Following the earnings report the stock price went down -23.043%.
Which hedge fund is a major shareholder of Orexo AB?
Currently, no hedge funds are holding shares in ORXOF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
ORXOF Company Deck
ORXOF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong scientific and programmatic progress (positive in vivo data for OX390, Izipry filing on track, OX640 progression, BARDA funding, and business development momentum) and valuable strategic assets (long IP life, AmorphOX platform interest). However, short-term financials are challenged by material one-off costs (GAIA settlement), ongoing DOJ uncertainty, substantial quarterly cash burn and low revenues. Management has clear plans to reduce run-rate OpEx and pursue partnerships and financing, but timing and DOJ resolution are key near-term risks.View all ORXOF earnings summariesTechnical Analysis
AlzeCure Pharma AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enzymatica AB
―
Enorama Pharma AB
―
Ownership Overview
―
Insiders
0.05% Mutual Funds
― Other Institutional Investors
99.95% Public Companies and
Individual Investors